# Dora Dias‐Santagata

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dora-dias-santagata/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,149 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 63 |
| i10-index | 107 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5006018613 |
| ORCID iD | https://orcid.org/0000-0002-1174-3972 |
| Works | 359 |

## Researcher papers

- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer](https://scholariq.org/papers/molecular-mechanisms-of-resistance-to-first-and-second-generation-alk-inhibitors/)
- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas](https://scholariq.org/papers/exome-sequencing-identifies-braf-mutations-in-papillary-craniopharyngiomas/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion](https://scholariq.org/papers/landscape-of-acquired-resistance-to-osimertinib-in-i-egfr-i-mutant-nsclc-and/)
- [Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models](https://scholariq.org/papers/synthetic-lethal-interaction-of-combined-bcl-xl-and-mek-inhibition-promotes/)
- [Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice](https://scholariq.org/papers/implementing-multiplexed-genotyping-of-non-small-cell-lung-cancers-into-routine/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)
- [Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma](https://scholariq.org/papers/widespread-chromosomal-losses-and-mitochondrial-dna-alterations-as-genetic/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)

## Researcher university

- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.